Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma.

@article{Ichinose2003RandomizedDP,
  title={Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma.},
  author={Yukito Ichinose and Keiichiro Genka and Terumoto Koike and Harubumi Kato and Yoh Watanabe and Takashi Mori and Sogo Iioka and Akira Sakuma and Mitsuo Ohta},
  journal={Journal of the National Cancer Institute},
  year={2003},
  volume={95 8},
  pages={605-10}
}
BACKGROUND Bestatin is a potent aminopeptidase inhibitor that has immunostimulant and antitumor activity. We conducted a prospective randomized, double-blind, placebo-controlled trial to determine whether postoperative adjuvant treatment with bestatin could prolong the survival of patients with completely resected stage I squamous-cell lung carcinoma. METHODS Patients with confirmed, resected stage I squamous-cell lung carcinoma were randomly assigned to receive either bestatin (30 mg) or… CONTINUE READING